Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma
Latest Information Update: 20 May 2024
At a glance
- Drugs MB-CART20.1 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Miltenyi Biotec GmbH
Most Recent Events
- 15 May 2024 Status changed from recruiting to discontinued because the risk-benefit assessment was not upto the mark.
- 20 Sep 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 20 Sep 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.